/SNTI
SNTI Stock - Senti Biosciences, Inc.
Healthcare|BiotechnologyNASDAQ
$1.20+2.56%
+$0.03 (+2.56%) • Dec 19
53
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.2
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.36
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+400.0%upside
Target: $6.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SNTI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.19 – $1.21
TARGET (TP)$6.00
STOP LOSS$1.10
RISK/REWARD1:48.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.09
52W High$5.10
52W Low$1.15
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $1.98M | $3.29M | $2.29M | $394,000 |
| Gross Profit | N/A | $1.98M | $3.29M | $2.29M | $394,000 |
| Gross Margin | N/A | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-61,039,000 | $-92,727,000 | $-62,084,000 | $-40,446,000 | $-24,694,000 |
| Net Income | $-52,790,000 | $-71,058,000 | $-58,210,000 | $-55,319,000 | $-19,862,000 |
| Net Margin | N/A | -3592.4% | -1771.5% | -2414.6% | -5041.1% |
| EPS | $-11.49 | $-20.94 | $-13.25 | $-12.67 | $-4.55 |
Company Overview
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
67%
Hold / Neutral
1
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
2 Bullish1 Neutral/Bearish
Price Targets
$8
Average Target
↑ 580.6% Upside
Now
$5
Low
$8
Average
$12
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 14th 2025 | H.C. Wainwright | Initiation | Buy | $12 |
| June 6th 2025 | Laidlaw | Initiation | Buy | $5 |
| October 7th 2022 | Morgan Stanley | Initiation | Equal Weight | $7.5 |
Earnings History & Surprises
SNTIBeat Rate
70%
Last 10 quarters
Avg Surprise
-165.9%
EPS vs Estimate
Beats / Misses
7/3
Last 12 quarters
Latest EPS
$-0.69
Q4 2025
EPS Surprise History
Q1 24
-1726.1%
$-4.20vs$-0.23
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
+78.6%
$-0.67vs$-3.13
Q2 25
-143.1%
$-1.41vs$-0.58
Q3 25
+37.8%
$-0.56vs$-0.90
Q4 25
-16.9%
$-0.69vs$-0.59
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 19, 2026 | $-0.43 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.59 | $-0.69 | -16.9% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.90 | $-0.56 | +37.8% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-0.58 | $-1.41 | -143.1% | ✗ MISS |
Q1 2025 | Mar 20, 2025 | $-3.13 | $-0.67 | +78.6% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | — | $-6.31 | — | — |
Q3 2024 | Aug 13, 2024 | — | $-2.45 | — | — |
Q2 2024 | May 9, 2024 | — | $-2.60 | — | — |
Q1 2024 | Mar 21, 2024 | $-0.23 | $-4.20 | -1726.1% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-4.80 | $-2.50 | +47.9% | ✓ BEAT |
Q3 2023 | Aug 11, 2023 | $-4.80 | $-4.20 | +12.5% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-4.80 | $-4.20 | +12.5% | ✓ BEAT |
Q1 2023 | Mar 22, 2023 | $-4.70 | $-4.20 | +10.6% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-5.20 | $-3.80 | +26.9% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | — | $-2.65 | — | — |
Q3 2022 | Aug 9, 2022 | — | $-2.70 | — | — |
Q1 2022 | Mar 7, 2022 | — | $-2.50 | — | — |
Q4 2021 | Nov 10, 2021 | — | $-2.61 | — | — |
Q3 2021 | Aug 6, 2021 | — | $-2.75 | — | — |
Q3 2021 | Jul 2, 2021 | — | $-0.00 | — | — |
Latest News
Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $13
📈 PositiveBenzinga•Dec 9, 2025, 08:07 PM
SNTI stock has given up its prior gain. Senti Biosciences shares were trading higher after the company announced new data from its ongoing multinational, multicenter clinical trial of SENTI-202
➖ NeutralBenzinga•Dec 9, 2025, 04:00 PM
Senti Biosciences shares are trading higher after the company announced new data from its ongoing multinational, multicenter clinical trial of SENTI-202
📈 PositiveBenzinga•Dec 9, 2025, 02:27 PM
Market-Moving News for December 9th
➖ NeutralBenzinga•Dec 9, 2025, 12:21 PM•Also: ,
Senti Biosciences Says FDA Grants Regenerative Medicine Advanced Therapy Designation To SENTI-202 For Treatment Of R/R Hematologic Malignancies, Including AML
📈 PositiveBenzinga•Dec 9, 2025, 12:17 PM
Senti Bio Receives FDA RMAT Designation For SENTI-202 In Relapsed Or Refractory AML After Orphan Drug Status, Backed By 50% ORR And 42% CR/CRh At RP2D
📈 PositiveBenzinga•Dec 9, 2025, 12:16 PM
Senti Bio Reports Updated Phase 1 SENTI-202 Data In R/R AML Showing 50% ORR, 42% CR/CRh With Mostly MRD-Negative Durable Responses And RMAT Support For Advancement Toward Pivotal Study
📈 PositiveBenzinga•Dec 9, 2025, 12:15 PM
Leerink Partners Initiates Coverage On Senti Biosciences with Outperform Rating, Announces Price Target of $6
📈 PositiveBenzinga•Nov 21, 2025, 02:34 PM
Senti Biosciences Q3 EPS $(0.69) Misses $(0.56) Estimate
📉 NegativeBenzinga•Nov 13, 2025, 10:02 PM
Senti Biosciences Says SENTI-202 Shows Deep, Durable Remissions In R/R AML With Selective Cancer Killing Ahead Of ASH 2025 Presentations
📈 PositiveBenzinga•Nov 3, 2025, 02:13 PM
HC Wainwright & Co. Initiates Coverage On Senti Biosciences with Buy Rating, Announces Price Target of $12
📈 PositiveBenzinga•Oct 14, 2025, 11:48 AM
Frequently Asked Questions about SNTI
What is SNTI's current stock price?
Senti Biosciences, Inc. (SNTI) is currently trading at $1.20 per share. The stock has moved +2.56% today.
What is the analyst price target for SNTI?
The average analyst price target for SNTI is $6.00, based on 1 analyst.
What sector is Senti Biosciences, Inc. in?
Senti Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SNTI's market cap?
Senti Biosciences, Inc. has a market capitalization of $0.03 billion, making it a small-cap company.
Does SNTI pay dividends?
No, Senti Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALGS
Aligos Therapeutics, Inc.
$10.68
Mkt Cap: $0.1B
BRNS
Barinthus Biotherapeutics plc
$0.74
Mkt Cap: $0.0B
COEP
Coeptis Therapeutics, Inc.
$14.66
Mkt Cap: $0.1B
CUE
Cue Biopharma, Inc.
$0.27
Mkt Cap: $0.0B
CVM
CEL-SCI Corporation
$4.91
Mkt Cap: $0.0B
GNTA
Genenta Science S.p.A.
$1.45
Mkt Cap: $0.0B
IPSC
Century Therapeutics, Inc.
$0.90
Mkt Cap: $0.1B
KPTI
Karyopharm Therapeutics Inc.
$6.94
Mkt Cap: $0.1B
MDCX
Medicus Pharma Ltd. Common Stock
$1.69
Mkt Cap: $0.0B
XFOR
X4 Pharmaceuticals, Inc.
$3.60
Mkt Cap: $0.0B
Explore stocks similar to SNTI for comparison